23.83
0.68 (2.94%)
| Previous Close | 23.15 |
| Open | 23.67 |
| Volume | 1,999,440 |
| Avg. Volume (3M) | 4,229,547 |
| Market Cap | 2,497,078,528 |
| Price / Earnings (Forward) | 16.98 |
| Price / Sales | 0.970 |
| Price / Book | 1.67 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -11.12% |
| Operating Margin (TTM) | -40.33% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 80.20% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 118.73% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -547.15 M |
| Levered Free Cash Flow (TTM) | -741.26 M |
| Return on Assets (TTM) | -2.19% |
| Return on Equity (TTM) | -23.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Sarepta Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Average | -2.50 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.42% |
| % Held by Institutions | 96.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Erste Asset Management Gmbh | 30 Sep 2025 | 2,685,945 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (Wells Fargo, 88.84%) | Buy |
| Median | 19.50 (-18.17%) | |
| Low | 5.00 (HC Wainwright & Co., -79.02%) | Sell |
| Average | 22.25 (-6.63%) | |
| Total | 4 Buy, 3 Hold, 1 Sell | |
| Avg. Price @ Call | 19.68 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 14 Jan 2026 | 5.00 (-79.02%) | Sell | 21.15 |
| Wedbush | 09 Dec 2025 | 32.00 (34.28%) | Buy | 22.17 |
| Barclays | 05 Nov 2025 | 20.00 (-16.07%) | Hold | 18.67 |
| Guggenheim | 05 Nov 2025 | 19.00 (-20.27%) | Buy | 18.67 |
| Mizuho | 05 Nov 2025 | 26.00 (9.11%) | Buy | 18.67 |
| Wells Fargo | 05 Nov 2025 | 45.00 (88.84%) | Buy | 18.67 |
| Baird | 04 Nov 2025 | 15.00 (-37.05%) | Hold | 16.20 |
| Piper Sandler | 30 Oct 2025 | 16.00 (-32.86%) | Hold | 23.25 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |